 | • レポートコード：MRC2012A2064 • 出版社/出版日：GlobalInfoResearch / 2020年12月21日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、101ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品、医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、CINV既存・パイプライン薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。CINV既存・パイプライン薬の種類別市場規模（アロキシ（パロノセトロン）、ゾフランジェネリック（オンダンセトロン）、キトリルジェネリック（グラニセトロン）、エメンド（アプレピタント）、アキンゼオ（ネツピタント-パロノセトロン）、サストール（徐放性グラニセトロン注射）、ローラピタント）、用途別市場規模（病院、専門クリニック、診断センター治療、病院薬局、ドラッグストア）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：GlaxoSmithKline、Merck、Helsinn、Heron Therapeutics、Tesaro、 ・地域別グローバル市場分析 2015年-2020年 ・CINV既存・パイプライン薬の北米市場（アメリカ、カナダ、メキシコ） ・CINV既存・パイプライン薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・CINV既存・パイプライン薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・CINV既存・パイプライン薬の南米市場（ブラジル、アルゼンチン） ・CINV既存・パイプライン薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：アロキシ（パロノセトロン）、ゾフランジェネリック（オンダンセトロン）、キトリルジェネリック（グラニセトロン）、エメンド（アプレピタント）、アキンゼオ（ネツピタント-パロノセトロン）、サストール（徐放性グラニセトロン注射）、ローラピタント ・用途別分析：病院、専門クリニック、診断センター治療、病院薬局、ドラッグストア ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global CINV Existing and Pipeline Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.1% in the forecast period of 2020 to 2025 and will expected to reach USD 1757.8 million by 2025, from USD 1556.1 million in 2019.
The CINV Existing and Pipeline Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
CINV Existing and Pipeline Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, CINV Existing and Pipeline Drugs market has been segmented into
Aloxi (palonosetron)
Zofran Generic (ondansetron)
Kytril Generic (granisetron)
Emend (aprepitant)
Akynzeo (netupitant-palonosetron)
SUSTOL (extended release granisetron injection)
Rolapitant
By Application, CINV Existing and Pipeline Drugs has been segmented into:
Hospitals
Specialty Clinics
Diagnostic Centers Therapeutics
Hospital Pharmacies
Drugstores
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global CINV Existing and Pipeline Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level CINV Existing and Pipeline Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global CINV Existing and Pipeline Drugs market.
The report offers in-depth assessment of the growth and other aspects of the CINV Existing and Pipeline Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and CINV Existing and Pipeline Drugs Market Share Analysis
CINV Existing and Pipeline Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, CINV Existing and Pipeline Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the CINV Existing and Pipeline Drugs sales, revenue and market share for each player covered in this report.
The major players covered in CINV Existing and Pipeline Drugs are:
GlaxoSmithKline
Merck
Helsinn
Heron Therapeutics
Tesaro
Among other players domestic and global, CINV Existing and Pipeline Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe CINV Existing and Pipeline Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of CINV Existing and Pipeline Drugs, with price, sales, revenue and global market share of CINV Existing and Pipeline Drugs in 2018 and 2019.
Chapter 3, the CINV Existing and Pipeline Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the CINV Existing and Pipeline Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, CINV Existing and Pipeline Drugs market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe CINV Existing and Pipeline Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 CINV Existing and Pipeline Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global CINV Existing and Pipeline Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Aloxi (palonosetron)
1.2.3 Zofran Generic (ondansetron)
1.2.4 Kytril Generic (granisetron)
1.2.5 Emend (aprepitant)
1.2.6 Akynzeo (netupitant-palonosetron)
1.2.7 SUSTOL (extended release granisetron injection)
1.2.8 Rolapitant
1.3 Market Analysis by Application
1.3.1 Overview: Global CINV Existing and Pipeline Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Diagnostic Centers Therapeutics
1.3.5 Hospital Pharmacies
1.3.6 Drugstores
1.4 Overview of Global CINV Existing and Pipeline Drugs Market
1.4.1 Global CINV Existing and Pipeline Drugs Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 GlaxoSmithKline
2.1.1 GlaxoSmithKline Details
2.1.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 GlaxoSmithKline SWOT Analysis
2.1.4 GlaxoSmithKline Product and Services
2.1.5 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Merck
2.2.1 Merck Details
2.2.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Merck SWOT Analysis
2.2.4 Merck Product and Services
2.2.5 Merck CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Helsinn
2.3.1 Helsinn Details
2.3.2 Helsinn Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Helsinn SWOT Analysis
2.3.4 Helsinn Product and Services
2.3.5 Helsinn CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Heron Therapeutics
2.4.1 Heron Therapeutics Details
2.4.2 Heron Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Heron Therapeutics SWOT Analysis
2.4.4 Heron Therapeutics Product and Services
2.4.5 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Tesaro
2.5.1 Tesaro Details
2.5.2 Tesaro Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Tesaro SWOT Analysis
2.5.4 Tesaro Product and Services
2.5.5 Tesaro CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global CINV Existing and Pipeline Drugs Sales and Market Share by Manufacturer (2018-2019)
3.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 CINV Existing and Pipeline Drugs Manufacturer Market Share in 2019
3.3.2 Top 6 CINV Existing and Pipeline Drugs Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global CINV Existing and Pipeline Drugs Sales and Market Share by Regions (2015-2020)
4.1.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Regions (2015-2020)
4.2 North America CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
4.3 Europe CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
4.5 South America CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Country
5.1.1 North America CINV Existing and Pipeline Drugs Sales and Market Share by Country (2015-2020)
5.1.2 North America CINV Existing and Pipeline Drugs Revenue and Market Share by Country (2015-2020)
5.2 United States CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
5.3 Canada CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
5.4 Mexico CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Country
6.1.1 Europe CINV Existing and Pipeline Drugs Sales and Market Share by Country (2015-2020)
6.1.2 Europe CINV Existing and Pipeline Drugs Revenue and Market Share by Country (2015-2020)
6.2 Germany CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
6.3 UK CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
6.4 France CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
6.5 Russia CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
6.6 Italy CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific CINV Existing and Pipeline Drugs Revenue and Market Share by Regions (2015-2020)
7.2 China CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
7.3 Japan CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
7.4 Korea CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
7.5 India CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
7.6 Southeast Asia CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
7.7 Australia CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Country
8.1.1 South America CINV Existing and Pipeline Drugs Sales and Market Share by Country (2015-2020)
8.1.2 South America CINV Existing and Pipeline Drugs Revenue and Market Share by Country (2015-2020)
8.2 Brazil CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
8.3 Argentina CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa CINV Existing and Pipeline Drugs Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa CINV Existing and Pipeline Drugs Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
9.3 Turkey CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
9.4 Egypt CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
9.5 South Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global CINV Existing and Pipeline Drugs Sales and Market Share by Type (2015-2020)
10.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Type (2015-2020)
10.3 Global CINV Existing and Pipeline Drugs Price by Type (2015-2020)
11 Global CINV Existing and Pipeline Drugs Market Segment by Application
11.1 Global CINV Existing and Pipeline Drugs Sales Market Share by Application (2015-2020)
11.2 Global CINV Existing and Pipeline Drugs Revenue Market Share by Application (2015-2020)
11.3 Global CINV Existing and Pipeline Drugs Price by Application (2015-2020)
12 Market Forecast
12.1 Global CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2021-2025)
12.2 CINV Existing and Pipeline Drugs Market Forecast by Regions (2021-2025)
12.2.1 North America CINV Existing and Pipeline Drugs Market Forecast (2021-2025)
12.2.2 Europe CINV Existing and Pipeline Drugs Market Forecast (2021-2025)
12.2.3 Asia-Pacific CINV Existing and Pipeline Drugs Market Forecast (2021-2025)
12.2.4 South America CINV Existing and Pipeline Drugs Market Forecast (2021-2025)
12.2.5 Middle East & Africa CINV Existing and Pipeline Drugs Market Forecast (2021-2025)
12.3 CINV Existing and Pipeline Drugs Market Forecast by Type (2021-2025)
12.3.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Type (2021-2025)
12.3.2 Global CINV Existing and Pipeline Drugs Market Share Forecast by Type (2021-2025)
12.4 CINV Existing and Pipeline Drugs Market Forecast by Application (2021-2025)
12.4.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Application (2021-2025)
12.4.2 Global CINV Existing and Pipeline Drugs Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global CINV Existing and Pipeline Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of CINV Existing and Pipeline Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global CINV Existing and Pipeline Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 8. GlaxoSmithKline CINV Existing and Pipeline Drugs Major Business
Table 9. GlaxoSmithKline CINV Existing and Pipeline Drugs Total Revenue (USD Million) (2018-2019)
Table 10. GlaxoSmithKline SWOT Analysis
Table 11. GlaxoSmithKline CINV Existing and Pipeline Drugs Product and Services
Table 12. GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Merck Basic Information, Manufacturing Base and Competitors
Table 14. Merck CINV Existing and Pipeline Drugs Major Business
Table 15. Merck CINV Existing and Pipeline Drugs Total Revenue (USD Million) (2018-2019)
Table 16. Merck SWOT Analysis
Table 17. Merck CINV Existing and Pipeline Drugs Product and Services
Table 18. Merck CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Helsinn Basic Information, Manufacturing Base and Competitors
Table 20. Helsinn CINV Existing and Pipeline Drugs Major Business
Table 21. Helsinn CINV Existing and Pipeline Drugs Total Revenue (USD Million) (2018-2019)
Table 22. Helsinn SWOT Analysis
Table 23. Helsinn CINV Existing and Pipeline Drugs Product and Services
Table 24. Helsinn CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Heron Therapeutics Basic Information, Manufacturing Base and Competitors
Table 26. Heron Therapeutics CINV Existing and Pipeline Drugs Major Business
Table 27. Heron Therapeutics CINV Existing and Pipeline Drugs Total Revenue (USD Million) (2018-2019)
Table 28. Heron Therapeutics SWOT Analysis
Table 29. Heron Therapeutics CINV Existing and Pipeline Drugs Product and Services
Table 30. Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Tesaro Basic Information, Manufacturing Base and Competitors
Table 32. Tesaro CINV Existing and Pipeline Drugs Major Business
Table 33. Tesaro CINV Existing and Pipeline Drugs Total Revenue (USD Million) (2018-2019)
Table 34. Tesaro SWOT Analysis
Table 35. Tesaro CINV Existing and Pipeline Drugs Product and Services
Table 36. Tesaro CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Global CINV Existing and Pipeline Drugs Sales by Manufacturer (2018-2019) (Kg)
Table 38. Global CINV Existing and Pipeline Drugs Revenue by Manufacturer (2018-2019) (USD Million)
Table 39. Global CINV Existing and Pipeline Drugs Sales by Regions (2015-2020) (Kg)
Table 40. Global CINV Existing and Pipeline Drugs Sales Market Share by Regions (2015-2020)
Table 41. Global CINV Existing and Pipeline Drugs Revenue by Regions (2015-2020) (USD Million)
Table 42. North America CINV Existing and Pipeline Drugs Sales by Countries (2015-2020) (Kg)
Table 43. North America CINV Existing and Pipeline Drugs Sales Market Share by Countries (2015-2020)
Table 44. North America CINV Existing and Pipeline Drugs Revenue by Countries (2015-2020) (USD Million)
Table 45. North America CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2015-2020)
Table 46. Europe CINV Existing and Pipeline Drugs Sales by Countries (2015-2020) (Kg)
Table 47. Europe CINV Existing and Pipeline Drugs Sales Market Share by Countries (2015-2020)
Table 48. Europe CINV Existing and Pipeline Drugs Revenue by Countries (2015-2020) (USD Million)
Table 49. Asia-Pacific CINV Existing and Pipeline Drugs Sales by Regions (2015-2020) (Kg)
Table 50. Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share by Regions (2015-2020)
Table 51. Asia-Pacific CINV Existing and Pipeline Drugs Revenue by Regions (2015-2020) (USD Million)
Table 52. South America CINV Existing and Pipeline Drugs Sales by Countries (2015-2020) (Kg)
Table 53. South America CINV Existing and Pipeline Drugs Sales Market Share by Countries (2015-2020)
Table 54. South America CINV Existing and Pipeline Drugs Revenue by Countries (2015-2020) (USD Million)
Table 55. South America CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2015-2020)
Table 56. Middle East & Africa CINV Existing and Pipeline Drugs Sales by Countries (2015-2020) (Kg)
Table 57. Middle East & Africa CINV Existing and Pipeline Drugs Sales Market Share by Countries (2015-2020)
Table 58. Middle East & Africa CINV Existing and Pipeline Drugs Revenue by Countries (2015-2020) (USD Million)
Table 59. Middle East & Africa CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2015-2020)
Table 60. Global CINV Existing and Pipeline Drugs Sales by Type (2015-2020) (Kg)
Table 61. Global CINV Existing and Pipeline Drugs Sales Share by Type (2015-2020)
Table 62. Global CINV Existing and Pipeline Drugs Revenue by Type (2015-2020) (USD Million)
Table 63. Global CINV Existing and Pipeline Drugs Revenue Share by Type (2015-2020)
Table 64. Global CINV Existing and Pipeline Drugs Sales by Application (2015-2020) (Kg)
Table 65. Global CINV Existing and Pipeline Drugs Sales Share by Application (2015-2020)
Table 66. Global CINV Existing and Pipeline Drugs Sales Forecast by Regions (2021-2025) (Kg)
Table 67. Global CINV Existing and Pipeline Drugs Market Share Forecast by Regions (2021-2025)
Table 68. Global CINV Existing and Pipeline Drugs Sales Forecast by Type (2021-2025) (Kg)
Table 69. Global CINV Existing and Pipeline Drugs Market Share Forecast by Type (2021-2025)
Table 70. Global CINV Existing and Pipeline Drugs Sales Forecast by Application (2021-2025)
Table 71. Global CINV Existing and Pipeline Drugs Market Share Forecast by Application (2021-2025)
Table 72. Direct Channel Pros & Cons
Table 73. Indirect Channel Pros & Cons
Table 74. Distributors/Traders/ Dealers List
List of Figures
Figure 1. CINV Existing and Pipeline Drugs Picture
Figure 2. Global Sales Market Share of CINV Existing and Pipeline Drugs by Type in 2019
Figure 3. Aloxi (palonosetron) Picture
Figure 4. Zofran Generic (ondansetron) Picture
Figure 5. Kytril Generic (granisetron) Picture
Figure 6. Emend (aprepitant) Picture
Figure 7. Akynzeo (netupitant-palonosetron) Picture
Figure 8. SUSTOL (extended release granisetron injection) Picture
Figure 9. Rolapitant Picture
Figure 10. CINV Existing and Pipeline Drugs Sales Market Share by Application in 2018
Figure 11. Hospitals Picture
Figure 12. Specialty Clinics Picture
Figure 13. Diagnostic Centers Therapeutics Picture
Figure 14. Hospital Pharmacies Picture
Figure 15. Drugstores Picture
Figure 16. Global CINV Existing and Pipeline Drugs Market Status and Outlook (2015-2025) (USD Million)
Figure 17. United States CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Canada CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Mexico CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Germany CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 21. France CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 22. UK CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Russia CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Italy CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 25. China CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Japan CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Korea CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 28. India CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Southeast Asia CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Australia CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 31. Brazil CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 32. Egypt CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 33. Saudi Arabia CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 34. South Africa CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 35. Turkey CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 36. Global CINV Existing and Pipeline Drugs Sales Market Share by Manufacturer in 2019
Figure 37. Global CINV Existing and Pipeline Drugs Revenue Market Share by Manufacturer in 2019
Figure 38. Top 3 CINV Existing and Pipeline Drugs Manufacturer (Revenue) Market Share in 2019
Figure 39. Top 6 CINV Existing and Pipeline Drugs Manufacturer (Revenue) Market Share in 2019
Figure 40. Key Manufacturer Market Share Trend
Figure 41. Global CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020) (Kg)
Figure 42. Global CINV Existing and Pipeline Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 43. Global CINV Existing and Pipeline Drugs Revenue Market Share by Regions (2015-2020)
Figure 44. Global CINV Existing and Pipeline Drugs Revenue Market Share by Regions in 2018
Figure 45. North America CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
Figure 46. Europe CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
Figure 47. Asia-Pacific CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
Figure 48. South America CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
Figure 49. Middle East & Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020)
Figure 50. North America CINV Existing and Pipeline Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 51. North America CINV Existing and Pipeline Drugs Sales Market Share by Countries (2015-2020)
Figure 52. North America CINV Existing and Pipeline Drugs Sales Market Share by Countries in 2018
Figure 53. North America CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 54. North America CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2018
Figure 55. United States CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020) (Kg)
Figure 56. Canada CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020) (Kg)
Figure 57. Mexico CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020) (Kg)
Figure 58. Europe CINV Existing and Pipeline Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 59. Europe CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2015-2020)
Figure 60. Europe CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2019
Figure 61. Germany CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020) (Kg)
Figure 62. UK CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020) (Kg)
Figure 63. France CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020) (Kg)
Figure 64. Russia CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020) (Kg)
Figure 65. Italy CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020) (Kg)
Figure 66. Asia-Pacific CINV Existing and Pipeline Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 67. Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share by Regions 2019
Figure 68. Asia-Pacific CINV Existing and Pipeline Drugs Revenue Market Share by Regions 2019
Figure 69. China CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020) (Kg)
Figure 70. Japan CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020) (Kg)
Figure 71. Korea CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020) (Kg)
Figure 72. India CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020) (Kg)
Figure 73. Southeast Asia CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020) (Kg)
Figure 74. South America CINV Existing and Pipeline Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 75. South America CINV Existing and Pipeline Drugs Sales Market Share by Countries in 2019
Figure 76. South America CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2019
Figure 77. Brazil CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020) (Kg)
Figure 78. Argentina CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020) (Kg)
Figure 79. Middle East and Africa CINV Existing and Pipeline Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 80. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Countries in 2019
Figure 81. Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2015-2020)
Figure 82. Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2019
Figure 83. Saudi Arabia CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020) (Kg)
Figure 84. Egypt CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020) (Kg)
Figure 85. Turkey CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020) (Kg)
Figure 86. South Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2015-2020) (Kg)
Figure 87. Global CINV Existing and Pipeline Drugs Sales and Growth Rate (2021-2025) (Kg)
Figure 88. Global CINV Existing and Pipeline Drugs Revenue and Growth Rate (2021-2025) (USD Million)
Figure 89. North America Sales CINV Existing and Pipeline Drugs Market Forecast (2021-2025) (Kg)
Figure 90. Europe Sales CINV Existing and Pipeline Drugs Market Forecast (2021-2025) (Kg)
Figure 91. Asia-Pacific Sales CINV Existing and Pipeline Drugs Market Forecast (2021-2025) (Kg)
Figure 92. South America Sales CINV Existing and Pipeline Drugs Market Forecast (2021-2025) (Kg)
Figure 93. Middle East & Africa Sales CINV Existing and Pipeline Drugs Market Forecast (2021-2025) (Kg)
Figure 94. Sales Channel: Direct Channel vs Indirect Channel
CINV既存・パイプライン治療薬の世界市場（～2026年） Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV). Market Analysis and Insights: Global CINV Existing and Pipeline Drugs Market The global CINV Existing and Pipeline Drugs market size i…- 化学療法誘発性悪心・嘔吐（CINV）治療薬の世界市場（～2026年） Market Analysis and Insights: Global Chemotherapy Induced Nausea and Vomiting （CINV） Drugs Market The global Chemotherapy Induced Nausea and Vomiting （CINV） Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Chemoth…
- ネツピタント-パロノセトロンFDCの世界市場（～2026年） The netupitant-palonosetron FDC is an oral therapy that targets two critical pathways associated with acute and delayed CINV by blockage of P/NK1 receptors. Netupitant in the central nervous system inhibits the binding of endogenous tachykinin neuropeptide substance, which prevents chemotherapy-indu…
- 化学療法誘発性悪心・嘔吐（CINV）治療薬の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market pl…
- 吸入・点鼻薬ジェネリック医薬品の世界市場（～2026年） Inhalation and Nasal Spray is a kind of drug used to relieve sneezing, runny, stuffy, or itchy nose and itchy, watery eyes caused by hay fever or other allergies. Quality control could pose an issue in the overall growth of generic inhalers and nasal spray sales, an issue that governments are trying…